See more : POONA DAL & OIL INDUSTRIES LTD (POONADAL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Innovent Biologics, Inc. (IVBXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innovent Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Global Energy Networks Corp. (GBNW) Income Statement Analysis – Financial Results
- Nanjing Railway New Technology Co.,Ltd. (301016.SZ) Income Statement Analysis – Financial Results
- Major Development Public Company Limited (MJD.BK) Income Statement Analysis – Financial Results
- Spire Healthcare Group plc (SPI.L) Income Statement Analysis – Financial Results
- United Natural Foods, Inc. (UNFI) Income Statement Analysis – Financial Results
Innovent Biologics, Inc. (IVBXF)
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 4.56B | 4.27B | 3.84B | 1.05B | 9.48M | 18.54M | 32.13M |
| Cost of Revenue | 1.81B | 930.99M | 573.04M | 387.76M | 124.88M | -1.31M | -71.47M | 0.00 |
| Gross Profit | 4.40B | 3.63B | 3.70B | 3.46B | 922.65M | 10.79M | 90.01M | 32.13M |
| Gross Profit Ratio | 70.89% | 79.57% | 86.58% | 89.91% | 88.08% | 113.84% | 485.54% | 100.00% |
| Research & Development | 2.23B | 2.87B | 2.48B | 1.85B | 1.29B | 1.22B | 611.92M | 384.65M |
| General & Administrative | 750.28M | 835.49M | 884.03M | 436.87M | 255.30M | 277.50M | 87.77M | 57.38M |
| Selling & Marketing | 3.10B | 2.59B | 2.73B | 1.34B | 1.19B | 136.01M | 9.94M | 5.03M |
| SG&A | 3.85B | 3.43B | 3.61B | 1.78B | 1.45B | 413.51M | 87.77M | 57.38M |
| Other Expenses | 0.00 | -90.20M | -45.13M | -130.69M | -41.38M | -4.34B | -51.01M | -123.20M |
| Operating Expenses | 5.07B | 6.21B | 6.05B | 3.50B | 2.70B | 1.56B | 643.27M | 413.27M |
| Cost & Expenses | 7.89B | 7.14B | 6.62B | 3.89B | 2.83B | 1.56B | 643.27M | 413.27M |
| Interest Income | 452.84M | 189.54M | 151.76M | 116.10M | 102.70M | 20.68M | 7.98M | 4.54M |
| Interest Expense | 98.62M | 101.70M | 62.46M | 68.35M | 59.49M | 68.97M | 57.23M | 53.80M |
| Depreciation & Amortization | 385.10M | 319.42M | 204.75M | 85.63M | 86.37M | 64.06M | 61.10M | 53.35M |
| EBITDA | -660.68M | -1.75B | -2.37B | -704.74M | -1.57B | -5.74B | -597.72M | -359.92M |
| EBITDA Ratio | -10.65% | -38.51% | -68.11% | -19.11% | -150.52% | -60,586.43% | -3,430.40% | -1,413.33% |
| Operating Income | -1.68B | -2.07B | -3.11B | -820.14M | -1.66B | -1.79B | -750.14M | -461.54M |
| Operating Income Ratio | -27.06% | -45.52% | -72.91% | -21.34% | -158.76% | -18,841.75% | -4,046.48% | -1,436.60% |
| Total Other Income/Expenses | 534.89M | -96.54M | 61.63M | -301.53M | -56.86M | -4.32B | -91.32M | -131.19M |
| Income Before Tax | -1.14B | -2.17B | -3.05B | -858.71M | -1.72B | -5.87B | -716.05M | -544.46M |
| Income Before Tax Ratio | -18.44% | -47.64% | -71.46% | -22.34% | -164.19% | -61,970.90% | -3,862.61% | -1,694.69% |
| Income Tax Expense | -116.50M | 8.80M | 87.04M | 139.71M | 56.86M | 27.48M | -244.37M | -150.97M |
| Net Income | -1.03B | -2.18B | -3.14B | -998.42M | -1.78B | -5.77B | -562.32M | -504.20M |
| Net Income Ratio | -16.56% | -47.83% | -73.50% | -25.97% | -169.62% | -60,899.99% | -3,033.33% | -1,569.40% |
| EPS | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| EPS Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| Weighted Avg Shares Out | 1.56B | 1.49B | 1.45B | 1.35B | 1.18B | 334.68M | 1.12B | 1.12B |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.49B | 1.46B | 1.36B | 1.18B | 334.68M | 1.12B | 1.12B |
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
Innovent Announces 2023 Interim Results and Business Updates
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
China's Innovent Biologics secures over $300 million investment from Sanofi
Source: https://incomestatements.info
Category: Stock Reports